Marylène Lecocq
Université catholique de Louvain
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Marylène Lecocq.
American Journal of Respiratory and Critical Care Medicine | 2011
Sandra Lo Re; Marylène Lecocq; Francine Uwambayinema; Yousof Yakoub; Monique Delos; Jean-Baptiste Demoulin; Sophie Lucas; Tim Sparwasser; Jean-Christophe Renauld; Dominique Lison; François Huaux
RATIONALE There is evidence that CD4(+) effector T lymphocytes (T eff) participate in the development of lung fibrosis, but the role of their CD4(+) regulatory T-cell (T reg) counterparts remains to be determined. OBJECTIVES To elucidate the contribution of T reg cells in a mouse model of lung fibrosis induced by silica (SiO(2)) particles. METHODS Lung T reg and T eff cells purified from SiO(2)-treated Foxp3-GFP transgenic mice were cocultured with naive lung fibroblasts or transferred to the lungs of healthy mice. DEREG mice, which express the diphtheria toxin receptor under the control of the foxp3 gene, were used to deplete T reg cells during fibrogenesis. MEASUREMENTS AND MAIN RESULTS CD4(+) Foxp3(+) T reg cells were persistently recruited in the lungs in response to SiO(2). T reg accumulation paralleled the establishment of pulmonary immunosuppression and fibrosis. T reg cells highly expressed platelet-derived growth factor (PDGF)-B via a TGF-β autocrine signaling pathway, directly stimulated fibroblast proliferation in vitro, and increased lung collagen deposition upon transfer in the lung of naive mice. The direct profibrotic effects of T reg cells were abolished by the inhibitor of the PDGF-B/TGF-β signaling pathway, imatinib mesylate. Neutralization of T reg-immunosuppressive activity resulted in enhanced accumulation of T eff cells and IL-4-driven pulmonary fibrogenesis, further demonstrating that T reg cells control T eff cell functions during inflammatory fibrosis. CONCLUSIONS Our study indicates that T reg cells contribute to lung fibrosis by stimulating fibroblasts through the secretion of PDGF-B in noninflammatory conditions and regulate detrimental T eff cell activities during inflammation-related fibrosis.
European Respiratory Journal | 2015
Sophie Gohy; Cloé Hupin; Chantal Fregimilicka; Bruno Detry; Caroline Bouzin; Héloïse P. Gaide Chevronnay; Marylène Lecocq; Birgit Weynand; Maha Zohra Ladjemi; Christophe E. Pierreux; Philippe Birembaut; Myriam Polette; Charles Pilette
In chronic obstructive pulmonary disease (COPD), epithelial changes and subepithelial fibrosis are salient features in conducting airways. Epithelial-to-mesenchymal transition (EMT) has been recently suggested in COPD, but the mechanisms and relationship to peribronchial fibrosis remain unclear. We hypothesised that de-differentiation of the COPD respiratory epithelium through EMT could participate in airway fibrosis and thereby, in airway obstruction. Surgical lung tissue and primary broncho-epithelial cultures (in air–liquid interface (ALI)) from 104 patients were assessed for EMT markers. Cell cultures were also assayed for mesenchymal features and for the role of transforming growth factor (TGF)-β1. The bronchial epithelium from COPD patients showed increased vimentin and decreased ZO-1 and E-cadherin expression. Increased vimentin expression correlated with basement membrane thickening and airflow limitation. ALI broncho-epithelial cells from COPD patients also displayed EMT phenotype in up to 2 weeks of culture, were more spindle shaped and released more fibronectin. Targeting TGF-β1 during ALI differentiation prevented vimentin induction and fibronectin release. In COPD, the airway epithelium displays features of de-differentiation towards mesenchymal cells, which correlate with peribronchial fibrosis and airflow limitation, and which are partly due to a TGF-β1-driven epithelial reprogramming. The COPD airway epithelium is programmed for mesenchymal transition via a TGF-β1-dependent process http://ow.ly/LhIQb
Allergy | 2014
Cloé Hupin; Sophie Gohy; Caroline Bouzin; Marylène Lecocq; Myriam Polette; Charles Pilette
Chronic rhinosinusitis (CRS) defines a group of disorders characterized by persistent inflammation of the sinonasal tract. Epithelial changes and structural remodelling are present, but whether epithelial differentiation is altered remains uncertain.
American Journal of Respiratory and Critical Care Medicine | 2014
Sophie Gohy; Bruno Detry; Marylène Lecocq; Caroline Bouzin; Birgit Weynand; Gimano D. Amatngalim; Yves Sibille; Charles Pilette
RATIONALE The generation of protective secretory IgA relies on the epithelial polymeric immunoglobulin receptor (pIgR). pIgR expression is reduced in chronic obstructive pulmonary disease (COPD), but correlation to disease severity and underlying mechanisms remains unknown. OBJECTIVES To address the hypothesis that pIgR down-regulation in COPD concerns severe disease in relation to aberrant programming of the bronchial epithelium. METHODS Surgical lung tissue and primary bronchial epithelium (cultured in air-liquid interface, ALI) obtained from a large series of patients (n = 116) were studied for pIgR expression and regulation. MEASUREMENTS AND MAIN RESULTS pIgR immunostaining in the bronchial epithelium is decreased in severe COPD. In contrast, pIgR transcription was up-regulated in smokers with or without COPD. In ALI (vs. submerged) cultures, pIgR expression was strongly induced, whereas pIgR expression and IgA-transcytosis capacity were decreased in cultures from subjects with severe COPD as compared with control subjects. In addition, COPD cultures released more transforming growth factor-β1 (TGF-β1), reflecting increased epithelial TGF-β1 immunostaining in COPD lung tissue. Finally, besides inducing epithelial dedifferentiation, exogenous TGF-β1 dose-dependently inhibited pIgR production, whereas pIgR increased on blockade of TGF-β1 activity during ALI differentiation. CONCLUSIONS pIgR down-regulation in COPD correlates with disease severity, and the bronchial epithelium reconstituted in vitro from these patients retains its aberrant imprinting for pIgR expression. This study also links pIgR down-regulation to TGF-β-driven reprogramming of the bronchial epithelium, which results in impaired lung IgA immunity in patients with COPD.
Allergy | 2013
Cloé Hupin; Philippe Rombaux; Holly Bowen; Hannah J. Gould; Marylène Lecocq; Charles Pilette
Immunoglobulin (Ig) A represents a first‐line defence mechanism in the airways, but little is known regarding its implication in upper airway disorders. This study aimed to address the hypothesis that polymeric Ig receptor (pIgR)‐mediated secretory IgA immunity could be impaired in chronic upper airway diseases.
Journal of Immunology | 2013
Marylène Lecocq; Bruno Detry; A. Guisset; Charles Pilette
We showed that IgA induces IL-10 in monocytes and dendritic cells. Because reciprocal inhibition exists between IL-10 and IL-12, we explored whether IgA could regulate this other immunoregulatory cytokine. In human monocytes and monocyte-derived dendritic cells preincubated with IFN-γ before stimulation by LPS, suppression of p40 and IL-12p70 production was observed upon IgA treatment during IFN-γ priming. Washout experiments and inhibition of IFN-γ–induced CXCL10 (IP-10) and FcγRI (CD64) indicated that inhibition by IgA occurred at both the LPS and IFN-γ levels. Inhibition was not affected by blockade of IL-10 or MAPK but involved FcαRI/CD89-mediated suppression of STAT1 phosphorylation. These data indicate that FcαRI ligation on human monocytes and dendritic cells inhibits IL-12 expression and type 1 activation by interfering with STAT1 activation.
European Respiratory Journal | 2015
Maha Zohra Ladjemi; Marylène Lecocq; Birgit Weynand; Holly Bowen; Hannah J. Gould; Jacques Van Snick; Bruno Detry; Charles Pilette
Despite their relevance to mucosal defense, production of IgA and the function of lung B-cells remain unknown in chronic obstructive pulmonary disease (COPD). We assessed IgA synthesis in the lungs of COPD (n=28) and control (n=21) patients, and regulation of B-cells co-cultured with in vitro-reconstituted airway epithelium. In COPD lung tissue, synthesis of IgA1 was increased, which led to its accumulation in subepithelial areas. In vitro, the COPD bronchial epithelium imprinted normal human B-cells for increased production of IgA (mainly IgA1) and maturation into CD38+ plasma cells. These effects were associated with upregulation of TACI (transmembrane activator and CAML interactor) and were observed under resting conditions, while being partly inhibited upon stimulation with cigarette smoke extract. Interleukin (IL)-6 and BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) were upregulated in the COPD epithelium and lung tissue, respectively; the IgA-promoting effect of the COPD bronchial epithelium was inhibited by targeting IL-6 and, to a lower extent, by blocking TACI. These data show that in COPD, the bronchial epithelium imprints B-cells with signals promoting maturation into IgA-producing plasma cells through the action of two epithelial/B-cell axes, namely the IL-6/IL-6 receptor and BAFF-APRIL/TACI pathways, while cigarette smoke partly counteracts this IgA-promoting effect. COPD epithelium induces B-cell maturation of IgA-producing plasma cells via IL-6/IL-6R and BAFF-APRIL/TACI pathways http://ow.ly/D7bR3
Clinical and Translational Allergy | 2013
Cloé Hupin; Philippe Rombaux; Marylène Lecocq; Charles Pilette
Background Transcytosis of immunoglobulin A (IgA) through polarized bronchial and sinonasal epithelial cells is mediated by the polymeric immunoglobulin receptor (pIgR), which represents the rate-limiting factor for this frontline protective mechanism in the airways. pIgR expression is decreased in COPD, lung cancer and nasopharyngeal carcinoma, while its role in sinonasal chronic inflammatory diseases has not been explored. The aim of this study was thus to assess pIgR expression in sinonasal mucosa of patient with chronic rhinosinusitis with (CRSwNP) or without polyps (CRSsNP) and in allergic rhinitis (AR), as well as IgA and SC (the released soluble part of the pIgR) in nasal secretions.
Clinical Immunology | 2016
Chong Shen; Bruno Detry; Marylène Lecocq; Charles Pilette
Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry | 2010
Cloé Hupin; Philippe Rombaux; Marylène Lecocq; Birgit Weynand; Yves Sibille; Charles Pilette